PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics

Xiaoli Sheng¹ ²†, Yunxian Li³†, Yixuan Li⁴, Wenlin Liu⁵, Zhongming Lu², Jiandong Zhan², Mimi Xu², Liangsi Chen², Xiaoning Luo², Gang Cai⁶* and Siyi Zhang²,1*

Abstract

Background: Advanced stage laryngeal squamous cell carcinoma (LSCC) presents a poor prognosis; thus, there is a great need to identify novel prognostic molecular markers. Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) is thought to be a novel prognostic factor in several cancers, but its role in LSCC remains unknown. Cancer stem cells (CSCs) are responsible for most instances of tumor recurrence and the development of drug resistance and have been proven to be present in head and neck cancers. Our preliminary study indicated that PLOD2 was elevated in LSCC tissues; therefore, we hypothesized that PLOD2 is related to the prognosis of LSCC patients and aimed to explore the role and underlying mechanism of PLOD2 in LSCC.

Methods: We validated the prognostic role of PLOD2 in 114 LSCC patients by immunohistochemistry. Stable PLOD2-overexpressing Hep-2 and FaDu cells were established and assessed by molecular biology and biochemistry methods both in vitro and in vivo.

Results: We confirmed that PLOD2 overexpression was correlated with poor prognosis in LSCC patients. PLOD2 overexpression strengthened the CSC-like properties of Hep-2 and FaDu cells, activated the Wnt signaling pathway and conferred drug resistance in LSCC in vitro and in vivo.

Conclusions: We found that PLOD2 could serve as a prognostic marker in patients with LSCC and confer drug resistance in LSCC by increasing CSC-like traits; in addition, a Wnt-responsive CSC pathway was identified.

Keywords: Laryngeal squamous cell carcinoma, PLOD2, Drug resistance, Cancer stem cells, Wnt/β-catenin pathway

Background

Laryngeal carcinoma is one of the most common head and neck malignancies, and the vast majority of cases are laryngeal squamous cell carcinoma (LSCC). At the time of initial diagnosis, approximately 60% of laryngeal cancer patients are diagnosed with clinical stage III or IV disease, which is known as advanced LSCC [1]. The 5-year overall survival (OS) rates of patients with advanced LSCC is still low due to relapse and resistance to treatment. Thus, there is a great need to understand the molecular mechanisms of LSCC tumorigenesis to identify novel prognostic molecular markers in order to develop novel therapeutic strategies.

Cancer stem cells (CSCs), a small population of cancer cells that retain stem cell-like properties [2], account for most of the development of drug resistance and tumor recurrence. CSCs have been proven to be present in various tumors, including those of lung [3], brain [4], breast [5], prostate [6], colon [7], ovarian [8], and head and neck cancer [9]. CSCs are commonly identified by surface and nonsurface biomarkers, which are conserved and specific. For most malignancies, CD133 and CD44 have been used as common biomarkers for CSCs [10–14]. Furthermore, cancer stem-like cells (CSLCs) were...
enriched among cancer side-population (SP) cells, so the CSCs could be regarded as CSLCs and SP cells.

Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), also known as LH2, TLH2 and BRKS2, is a membrane-bound homodimeric enzyme that specifically hydroxylates lysines in the telopeptide of procollagens [15]. This enzyme is encoded by the PLOD2 gene, which has been implicated in the extracellular matrix formation and various pathological processes. Importantly, abnormal PLOD2 expression has been observed in many types of cancer. PLOD2 was found to be overexpressed in bladder cancer [16], oral carcinoma [17], hepatocellular carcinoma [18], breast cancer [19], sarcoma [20], and renal cell carcinoma [21] and was closely related to a poor prognosis. However, PLOD2 expression has shown no differences between gastric adenocarcinoma versus normal tissues and has consistently shown no relation with prognosis in gastric cancer based on the Kaplan-Meier plotter of the datasets from Oncomine™ database. The function of PLOD2 in the collagen cross-link switch and tumor cell invasion and migration has been confirmed in relation to metastasis [15]. Therefore, PLOD2 is thought to be a novel prognostic factor in several types of cancer. However, the role of PLOD2 in laryngeal cancer is unknown, and the mechanism of PLOD2 in malignancies remains largely unexplored.

In our preliminary work, we found that PLOD2 expression was significantly increased in LSCC and was closely related to the prognosis of LSCC patients. We assumed that PLOD2 is an indicator of prognosis in LSCC patients and plays a key role in the progression of laryngeal cancer. Here, we validated this assumption in 114 LSCC patients and attempted to determine the underlying mechanism. Finally, we report a novel role of PLOD2 in enhancing CSC-like traits and conferring drug resistance in LSCC via the Wnt/β-catenin signaling pathway.

Methods
Patients and specimens
Specimens were collected from 114 archives of patients with LSCC who underwent surgical resection at the Department of Head and Neck Surgery of Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences (Guangzhou, China) from 2008 to 2015. The tumor and paired normal adjacent tissue samples were collected from each patient. All samples for qRT-PCR were obtained from the surgically resected material, immediately placed in RNAlater TissueProtect Tubes (Qiagen, Hilden, Germany) and stored at –80 °C. Written informed consent was obtained beforehand from all patients, and the protocol was approved by the Ethical Committee of Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences. The median age of the patients was 62 years (range 43–85 years). There were 106 male and 8 female patients. The clinicopathological characteristics of the patients and samples are shown in Table 1. The patients were followed by telephone every 3 months during the first 2 years postoperatively and every 6 months thereafter until death.

Immunohistochemical (IHC) staining and evaluation
Paraffin-embedded LSCC tissue sections with a thickness of 50um were prepared, and IHC staining was performed using antibodies against PLOD2, CD44 and CD133. The staining results were evaluated and scored based on both the proportion of positively stained tumor cells and the intensity of staining, and analyzed by two independent pathologists in a blinded manner. The staining index (SI) was calculated as the product of the staining intensity and the proportion of positive cells. The staining intensity score was defined as: no staining = 0, weak staining (light yellow) = 1, moderate staining (yellow brown) = 2; strong staining (brown) = 3. Cell proportions were expressed as follows: 0 (no positive cells), 1 (<25% positive cells), 2 (26–50% positive cells), 3 (51–75% positive cells), 4 (>75% positive cells). Using this method of assessment, we evaluated protein expression by determining the SI, with possible scores of 0, 1, 2, 3, 4, 6, 8, 9, and 12. High- and low-expression samples were defined as those with an SI ≥6 or SI < 6 respectively.

Cell culture and stable cell line establishment
FaDu and Hep2 cell lines, the human head and neck squamous cell carcinoma lines, were selected as they are the available laryngeal cell lines in China (both from American Type Culture Collection, Manassas, VA, USA). Cells were maintained in DMEM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA) and were maintained in a humidified incubator at 37 °C with 5% CO2.

For stable cell line establishment, the indicated plasmids (pSin-EF2-puro-retro-PLOD2 and pSuper-puro-retro-PLOD2-RNAi) were packed into retrovirus in 293 T cells. Then, the viruses were harvested and FaDu and Hep2 cells were infected. After infection for 48 h, the cells were selected with medium containing puromycin (0.5 μg/ml) over 1 week.

qRT-PCR
Total RNA was extracted from the LSCC tissue samples and cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). qRT-PCR was performed using SYBR Green (Takara, Dalian, China) according to instruction of the manufacturer. The qRT-PCR results were analyzed, and the relative mRNA levels were calculated using the 2−ΔΔCt method. All experiments were performed at least three times in triplicate. The primer sequences used are provided in Table 2.
Western blotting

Tissue or cell lysates containing 20 μg of protein were prepared, and electrophoresed on a 10% SDS-PAGE gel under denaturing conditions, subsequently transferred to a PVDF membrane by electroblotting. The membrane was blocked in 5% nonfat milk for 60 min at room temperature, then incubated with the primary antibodies overnight at 4 °C. After washing with TBST three times, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (BOSTER, CA, USA) for 120 min at room temperature. The antibodies used included anti-PLOD2 mouse monoclonal antibody (1:3000 dilution; mab4445, R&D); anti-CD44, anti-CD133, anti-β-catenin rabbit polyclonal antibody (1:3000 dilution; 9582, CST), anti-myc mouse monoclonal antibody (1:3000; AM926, Beyotime), anti-MDR1 rabbit polyclonal antibody (1:3000; BA1351, BOSTER), anti-MRP antibody, anti-caspase-3 mouse monoclonal antibody (1:3000; SC-7272, SANTA), α-tubulin monoclonal mouse monoclonal antibody (1:3000 dilution; T9026, Sigma-Aldrich), and anti-GAPDH antibody (1:3000 dilution; BM1623, BOSTER).

Tumor sphere formation assay

Cells were trypsinized and seeded in six-well ultralow attachment culture plates at a density of 500 cells/well, cultured in DMEM/F12 serum-free medium (Invitrogen) with 2% B-27 Supplement (Invitrogen), 0.4% bovine serum albumin (BSA, Sigma-Aldrich), 20 ng/ml basal fibroblast growth factor (bFGF, PeproTech, Rocky Hill, NJ, USA), 20 ng/ml epidermal growth factor (EGF, PeproTech), and 5 μg/ml insulin (Sigma-Aldrich) for 11 days at 37 °C with 5% CO2. Subsequently, the numbers of spheres were counted under a microscope.

Analysis of the SP cell fraction

Hep-2 and FaDu cells were used in the SP assay to identify stem cells that overexpressed PLOD2 and could transport Hoechst 33342 dye. The cells were suspended in RPMI 1640 medium, which containing 2% fetal bovine serum (FBS) and 2 mM DMEM, at 1 x 10^6 cells per milliliter, then incubated at 37 °C for 20 min. Subsequently, Hoechst 33342 dye (Invitrogen) was added to a final concentration of 5 μg/mL (8.1 μM) from a 1 mg/mL stock solution, then the cells were incubated with cells for 90 min under shaking in a 37 °C bath. The control cells were incubated with 50 μM verapamil (Sigma Chemicals Co.) at 37 °C for 15 min.

Table 1: Clinicopathological characteristics of patient samples and expression of PLOD2 in laryngeal cancer.

| Parameters | Number of cases (%) |
|------------|---------------------|
| Gender     |                     |
| Male       | 106 (93.0)          |
| Female     | 8 (7.0)             |
| Age (years)|                     |
| < 62       | 56 (49.1)           |
| ≥ 62       | 58 (50.9)           |
| Clinical stage |               |
| I          | 38 (33.3)           |
| II         | 16 (14.0)           |
| III        | 28 (24.6)           |
| IV         | 32 (28.1)           |
| T classification |              |
| T1&T2      | 59 (51.8)           |
| T3         | 29 (25.4)           |
| T4         | 26 (22.8)           |
| N classification |           |
| N0         | 86 (75.4)           |
| N1 & N2 & N3 | 28 (24.6)    |
| M classification |             |
| M0         | 103 (90.4)          |
| M1         | 11 (9.6)            |
| Thyroid cartilage invasion |     |
| No         | 88 (77.2)           |
| Yes        | 26 (22.8)           |
| Type       |                     |
| Supraglottic | 35 (30.7)  |
| Subglottic  | 4 (3.5)             |
| Glottic     | 74 (64.9)           |
| Transglottic | 1 (0.9)       |
| Expression of CD44 |        |
| Low expression | 57 (50.0) |
| High expression | 57 (50.0) |
| Expression of CD133 |       |
| Low expression | 62 (54.4) |
| High expression | 52 (45.6) |
| Relapse status (at follow-up) | |
| No         | 78 (68.4)           |
| Yes        | 36 (31.6)           |
| Vital status (at follow-up) |      |
| Alive      | 93 (81.6)           |
| Dead       | 21 (18.4)           |

Table 1: Clinicopathological characteristics of patient samples and expression of PLOD2 in laryngeal cancer (Continued).

| Parameters | Number of cases (%) |
|------------|---------------------|
| Expression of PLOD2 |       |
| Low expression | 59 (51.8) |
| High expression | 55 (48.2) |
min before the addition of Hoechst 33342 dye. Hoechst 33342-labeled cells were analyzed on an FACS alibur flow cytometer (BD Biosciences), and cell aggregates were discarded from the analysis by doublet discrimination. SP cells were visualized or sorted by red (FL8) vs blue (FL7) ultraviolet channels both in linear mode.

Flow cytometry analysis
After transfection for 48 h, the cells were harvested by trypsinization and washed twice with cold phosphate-buffered saline (PBS). Then, the cells were resuspended in binding buffer and stained with 3.5 μL of Annexin V-FITC and 5 μL of propidium iodide (PI) for 15 min at room temperature in the dark, according to the manufacturer’s instructions. Apoptotic cells were observed using a FACS-Calibur flow cytometer system (BD Biosciences, San Jose, CA, USA) and analyzed using Summit5.2 software (Beckman Coulter, Indianapolis, IN). Flow cytometry analysis of Hoechst 33342 staining was performed on cells stably expressing PLOD2 or pBabe (vector) (upper panel). FTC (5 μM) was added before Hoechst 33342 staining (lower panel). The proportion of cells in the SP fraction was then presented.

Tumor xenografts
All animal experiments were approved by the Ethical Committee of Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences. BALB/c-nu mice (5–6 weeks old, Guangdong Animal Laboratory, Guangzhou, China) were used in this study. The mice were maintained under pathogen-free conditions according to the institutional guidelines for animal welfare. The mice were injected subcutaneously with 1 × 10^5 cells. Forty mice were randomly divided into four groups and injected with equal numbers of cells, and tumor formation was monitored for up to 10 days. Every group was allocated into 2 subgroups. Then one subgroup were treated with cisplatin (5 mg/kg, intraperitoneal injection, once a week) for another 20 days and the other subgroup as control. The length and width of tumors were measured with calipers, and the volumes were calculated using the equation (length× width^2)/2. After the mice were euthanized, the tumors were excised and used to pathological examination.

TOP/FOP-flash assay
Hep-2 and FaDu cells were plated in 24-well plates. Then cells were transiently transfected with plasmids containing firefly luciferase reporters and recombinant promoter reporter constructs. Luciferase and renilla signals was measured after incubation for 48 h by using the Dual Luciferase Assay kit (Promega, Madison, WI). Each experiment was performed at least three times in triplicate according to the manufacturer’s instructions.

Table 2 The primer sequences were used in qRT-PCR

| Gene | F | R |
|------|---|---|
| PLOD2 | CATGGACACAGGATAATGGCTG | AGGGGTGTGGTGTCAATAAAAA |
| CD44 | GAAAGATTTGGACAGGAC | CGTGGTGTGGTAAATGAGGTA |
| CD133 | TTTGGATCATATGCTTCTTG | CAGTGGATGCTTTCTGGAA |
| MMP2 | TACAGGATCTGCTACACACC | GGTCAATCGTCCTCAGACT |
| TCF4 | CAAGCACCAGGGCTACAATA | CCAGGGTATTTCATCCCACTG |
| SNAIL1 | TGGGAGCTAACTACACCAGGA | AGATGCAGCTGGGACAGGAG |
| β-actin | GTCATCTGGCCTCGTGT | GCTGTCACCTTACCCTGTTCC |
| MYC | GGCTCTGGCAAAAGTGCA | CTGCGTAGTGTGCTGTAGTG |
| NANO5 | TTTGGGCTGCTGAAGAAAACCT | AGGGGCTGTGCTGAAATAGCAG |
| ABCG2 | CAGTGAGAGGCAATCTCGT | ACCCTGTTAAATCCGTTCGTTTT |
| KLF4 | CCCCAGAGAAAGGAGCTCCC | CAGGTCAGAGAGAGTGTGAA |
| OCT4 | CAAAAGGAAAACCTCGTGGC | TCTCACTCGGTTCCTGATACTG |
| GAPDH | TCCTCTGACTTTACACAGGACAC | CACCCGTTGCTGATGGAATTCC |

Statistical analysis
The SPSS statistical software package (version 20.0) was used for all statistical calculations. The difference in PLOD2 expression between the LSCC and the paired normal adjacent tissues and the correlations between the protein expression levels and clinicopathological variables were analyzed using the Chi-square test or Fisher’s exact test. The differences among the groups were compared by one-way ANOVA, and the data are expressed as the mean ± SD. The statistical differences were set at P < 0.05.
**Results**

**PLOD2 overexpression is correlated with progression and a poor prognosis in LSCC patients**

We found that PLOD2 was highly expressed in head and neck squamous carcinoma in the publicly available human cancer datasets of The Cancer Genome Atlas (TCGA). To determine the difference of PLOD2 expression in LSCC, we performed qRT-PCR and western blot analyses in 8 pairs of human laryngeal cancer tissues and the adjacent normal laryngeal tissues, and revealed that PLOD2 was up-regulated at both the protein and mRNA levels in laryngeal cancer tissues (Fig. 1), suggesting that PLOD2 is upregulated in human laryngeal cancer. Consistently, we validated not only that the level of PLOD2 protein expression was upregulated in the LSCC tissues compared with that in the paired adjacent normal tissues by the IHC staining of 114 archived LSCC tissues but also that PLOD2 expression increased along with tumor progression. Furthermore, we found similar trends in the expression of CD44/CD133 (Fig. 2) accompanied with PLOD2 in tissues. CD44 and CD133 have been widely used as markers to identify CSCs.

The clinical significance of the high PLOD2 expression was further assessed (Table 1). According to the SI, PLOD2 expression was divided into the following two levels: high expression (PLOD2 high, \( n = 55 \)) and low expression (PLOD2 low, \( n = 59 \)). We found that PLOD2 expression was positively correlated with the clinical, T, N, and M stage and the expression of CD44/CD133 \( (P < 0.05) \) (Fig. 2, Table 3).

We further analyzed the correlations between the clinicopathological features and prognosis of the LSCC patients. All the variables were entered stepwise into the multivariable Cox proportional hazard model by the forward conditional method. M stage (HR = 3.463; 95% CI 1.087–11.031; \( P = 0.036 \)), thyroid cartilage invasion (HR = 3.180; 95% CI 1.136–8.898; \( P = 0.028 \)) and high PLOD2 expression (HR = 4.742, 95% CI 1.452–15.485; \( P = 0.010 \)) were independent prognostic factors of OS in the patients with LSCC (Table 4), which is consistent with the results of the univariable analysis.

Furthermore, Kaplan-Meier plotter revealed that patients with high PLOD2 expression had shorter 5-year OS \( (P = 0.000) \), and the same correlation was found between CD44/CD133 expression and 5-year OS (Fig. 3a). Intriguingly, CD44/CD133 expression was high in the majority of the tissues with high PLOD2 expression, and vice versa (Fig. 3b).

These results reveal that PLOD2 overexpression might promote LSCC progression, leading to poor clinical outcomes. Due to the correlation between PLOD2 and CD44/CD133 expression, PLOD2 might contribute to increasing cancer cell-like characteristics in LSCC.
PLOD2 contributes to the CSC-like properties of Hep-2 and FaDu cells

Stably infected Hep2 and FaDu cells were established with PLOD2 overexpressed and silenced (Fig. 4a). SP cells could efflux dye and fell to the “side” of the bulk of the positively stained cells in the FACS analysis plots [22]. It has been confirmed that SP cells have stem cell-like characteristics [23]. In the study, SP cells were used to validate the CSCs characteristic. The flow cytometry assays revealed smaller SP+ subpopulations among the PLOD2 siRNA-treated Hep-2 and FaDu cells compared than the controls (Fig. 4b).

Moreover, we found that silencing PLOD2 strongly inhibited Hep-2 and FaDu tumor sphere formation, generating approximately 2-fold fewer spheres with an approximately 2-fold lower cell content compared with that in the control cells (Fig. 4c). These results suggest that PLOD2 is essential for the maintenance of LSCC stem cell properties and inhibiting apoptosis. Subsequently, we analyzed the expression of classic embryonic stem cell transcription factors, including OCT4, Nanog, KLF4 and ABCG2 at the mRNA and protein levels (Fig. 4d, e). These four genes were up-regulated in the PLOD2-overexpressing cells. Hence, PLOD2 may activate the above genes to increase CSC-like characteristics via a certain signaling pathway.
Upregulation of PLOD2 confers drug resistance in LSCC in vitro and in vivo

Few studies have examined the association between PLOD2 and drug resistance, and abnormal regulation of apoptosis attributes for most of drug resistance. To investigate the anti-apoptotic role of PLOD2 in LSCC progression, Hep-2 and FaDu cells stably expressing PLOD2 were established (Fig. 3a). The percentage of apoptotic cells among PLOD2-overexpressing LSCC cells treated with a drug (cisplatin, DDP) was much lower than that among the control cells but much higher than that among cells with silenced PLOD2 expression.

Table 3 Correlation between PLOD2 expression and clinicopathological characteristics of laryngeal cancer patients

| Characteristics          | PLOD2                      | χ² test | Fisher’s exact test |
|--------------------------|----------------------------|---------|---------------------|
|                          | Low, no. cases (%)         |         |                     |
|                          | High, no. cases (%)        |         |                     |
| Clinical stage           |                            |         |                     |
| I&II                     | 38 (64.4)                  | < 0.001 | < 0.001             |
|                          | 16 (29.1)                  |         |                     |
| III&IV                   | 21 (35.6)                  | < 0.001 | < 0.001             |
|                          | 39 (70.9)                  |         |                     |
| T classification         |                            |         |                     |
| T1& T2                   | 42 (71.2)                  | < 0.001 | < 0.001             |
|                          | 17 (30.9)                  |         |                     |
| T3& T4                   | 17 (28.8)                  | 0.051   | 0.080               |
|                          | 38 (69.1)                  |         |                     |
| N classification         |                            |         |                     |
| No                       | 49 (83.1)                  | 0.087   | 0.116               |
|                          | 37 (67.3)                  |         |                     |
| N1& N2& N3               | 10 (16.9)                  | 0.051   | 0.080               |
|                          | 18 (32.7)                  |         |                     |
| M classification         |                            |         |                     |
| No                       | 56 (94.9)                  |         |                     |
|                          | 47 (85.5)                  |         |                     |
| Yes                      | 3 (5.1)                    | 8 (14.5) |                     |
| Expression of CD44       |                            | < 0.001 | < 0.001             |
| Low expression           | 50 (84.7)                  |         |                     |
|                          | 7 (12.7)                   |         |                     |
| High expression          | 9 (15.3)                   |         |                     |
|                          | 48 (87.3)                  |         |                     |
| Expression of CD133      |                            | < 0.001 | < 0.001             |
| Low expression           | 46 (78.0)                  |         |                     |
|                          | 16 (29.1)                  |         |                     |
| High expression          | 13 (22.0)                  |         |                     |
|                          | 39 (70.9)                  |         |                     |
| Age (years)              |                            |         |                     |
| < 62                     | 30 (50.8)                  | 0.703   | 0.712               |
|                          | 26 (47.3)                  |         |                     |
| ≥ 62                     | 29 (49.2)                  |         |                     |
|                          | 29 (52.7)                  |         |                     |

Table 4 Univariate and multivariate analysis of factors associated with overall survival in 114 laryngeal cancer patients

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR (95% CI)         | P values              |
|                          |                     |                       |
| Age                      | 0.928 (0.386–2.233) | 0.868                 |
| Gender                   | 1.857 (0.248–13.910) | 0.547                 |
| T stage                  | 8.280 (2.408–28.478) | 0.001*                |
|                          | 5.624 (1.594–19.840) | 0.007*                |
| N stage                  | 2.229 (0.910–5.461)  | 0.080                 |
|                          | 0.081               | 0.776                 |
| M stage                  | 3.935 (1.418–10.917) | 0.009*                |
|                          | 2.744 (0.987–7.629)  | 0.053                 |
| Clinical stage           | 6.252 (1.827–21.396) | 0.004*                |
|                          | 0.398               | 0.528                 |
| Relapse                  | 3.377 (1.395–8.175)  | 0.007*                |
|                          | 2.153               | 0.142                 |
| Thyroid cartilage invasion| 4.005 (1.634–9.819) | 0.002*                |
|                          | 0.699               | 0.403                 |
| CD44                     | 5.845 (1.936–17.647) | 0.002*                |
|                          | 1.459               | 0.227                 |
| CD133                    | 3.769 (1.436–9.891)  | 0.007*                |
|                          | 0.626               | 0.429                 |
| PLOD2                    | 6.720 (2.193–20.588) | 0.001*                |
|                          | 4.559 (1.356–15.325) | 0.014*                |

HR hazard ratio, CI confidence interval
* p < 0.05
Moreover, the IC50 value of the drug (DDP) was significantly decreased in the PLOD2-overexpressing LSCC cells but increased in the cells with silenced PLOD2 expression (Fig. 5b), suggesting that PLOD2 enhanced the resistance of LSCC cells to DDP in vitro.

To validate the contribution of PLOD2 of laryngeal cancer to chemoresistance, we used nude mice model. The nude mice were divided into four groups and subcutaneously inoculated with Hep-2 cells transfected with vector, PLOD2, scrambled, and PLOD2 shRNA (shPLOD2) respectively. Then, the mice were treated with DDP once a week after 10 days. As shown in Fig. 6a and c, treatment with shPLOD2 plus DDP resulted in a significant reduction in tumor growth; however, compared with the control, PLOD2 overexpression resulted in a significant increase in tumor growth. Interestingly, the protein level of cleaved caspase-3 was significantly decreased in PLOD2-overexpressing Hep-2 cells (Fig. 6b).

**Upregulation of PLOD2 activates the Wnt signaling pathway in LSCC cells**

By analyzing the PLOD2 mRNA expression levels and Wnt-regulated gene signatures in laryngeal cancer cells, we found that PLOD2 overexpression upregulated the downstream genes of the Wnt signaling pathway (Fig. 7a). Thus, TOP-Flash and FOP-Flash reporters co-transfected with PLOD2 overexpression were constructed to determine whether PLOD2 modulates the canonical Wnt/β-catenin...
signaling pathway. As expected, the overexpression of PLOD2 significantly increased the activity of TOP/FOP, whereas the silencing of PLOD2 significantly reduced the reporter activity (Fig. 7b). Moreover, western blotting revealed that the levels of c-myc and β-catenin, which are downstream genes of the Wnt signaling pathway, were dramatically upregulated in the PLOD2-overexpressing cells but downregulated in the cells with silenced PLOD2 expression (Fig. 7c). As shown by western blotting results, the expression of the drug resistance-related genes MDR-1 and MRP was significantly elevated in the PLOD2-overexpressing cells (Fig. 7c).

**Discussion**

Despite many advances in diagnostic methods and treatments, patients with advanced LSCC experience tend to relapse and metastasize and have a poor prognosis. Previous studies have suggested that PLOD2 is overexpressed in sarcoma [20], bladder cancer [16], renal cell carcinoma [21], glioblastoma [24], cervical cancer [25], oral carcinoma [17], bone metastasis [26] and other types of cancers [15]. The overexpression of PLOD2 is closely related to a poor prognosis in lung cancer and breast cancer, based on the Kaplan-Meier analysis. In our study, PLOD2 was overexpressed in LSCC tissues, and the LSCC patients with PLOD2 overexpression presented a lower OS rate; additionally, the patients with advanced-stage LSCC had higher PLOD2 expression. Hence, consistent with previous research on other malignancies, we showed that PLOD2 might be a biomarker of a poor prognosis in LSCC.

To determine the role of PLOD2 in the progression of LSCC, Hep-2 and FaDu cell lines were engineered to validate the function of PLOD2 in vitro. The flow cytometry results show smaller SP+ subpopulations among Hep-2 and FaDu cells with silenced PLOD2 expression than among the controls. In addition, the levels of CSC surface markers were upregulated in the PLOD2-overexpressing cells. To date, there has been little research on correlations between
PLOD2 and CSCs. In 1996, PLOD2 was first reported in breast cancer research by Smith [15]. Recently, fundamental evidence suggests that PLOD2 plays critical roles in the progression of cancer. The function and mechanism of PLOD2 in several types of cancer have been explored. The published reports suggest that PLOD2 plays a key role in collagen cross-linking, promoting tumor cell invasion and migration [27]. As functional studies have shown, PLOD2 hydroxylates telopeptidyl lysine residues on collagen, lowers levels of lysine aldehyde-derived cross-links, increases tumor stiffness, and enhances tumor cell invasion and metastasis [28]. In this study, we found that the expression of CD44 and CD133 increased as PLOD2 expression increased at both the mRNA and protein levels. In addition, some other markers of stem-like cells, such as ABCG2, KLF4, OCT4, and Nanog, co-expressed with PLOD2 were found to be highly expressed. In vitro, we also found that PLOD2 overexpression in Hep-2 and FaDu cells strongly promoted tumor sphere formation. Meanwhile, flow cytometry analysis revealed smaller SP+ subpopulations among Hep-2 and FaDu cells with silenced PLOD2 expression compared with those among the controls. Altogether, these data suggest that PLOD2 could enhance the CSC-like phenotype of laryngeal cancer cells and that PLOD2 plays a novel role in malignancies.

CSCs are responsible for tumor relapse, metastasis, and therapy resistance. Numerous studies emerged focusing on the contribution of CSCs to the development of multidrug resistance (MDR) in many types of cancers. In this study, we found that PLOD2 overexpression conferred drug resistance in LSCC in vitro and in vivo. Thus, PLOD2 may contribute to drug resistance in LSCC by maintaining CSC-like characteristics.

**Fig. 5** PLOD2 could promote drug resistance in laryngeal cancer cells. a Apoptotic scatter plot; Annexin V-FITC and PI staining of the indicated cells treated with DDP (50 μM) for 48 h. b IC50 of DDP in the indicated cells. Each bar represents the mean ± SD of five independent experiments. *P < 0.05. FITC, fluorescein isothiocyanate; PI, propidium iodide.
**Fig. 6** PLOD2 overexpression contributes to drug resistance in Hep-2 cells in vivo. 

- **a** Representative photographs of tumors isolated from the experimental mice (with/without DDP treatment).
- **b** Cleaved caspase 3 was significantly decreased in PLOD2-overexpressing Hep-2 cells.
- **c** Tumor volumes of the experimental mice during the treatment period. Each bar represents the mean ± SD of five independent experiments.

**Fig. 7** PLOD2 overexpression could activate the Wnt signaling pathway.

- **a** The mRNA levels of downstream genes of the Wnt signaling pathway (c-myc, CD44, Snail, TCF4, and MMP-2) were upregulated by PLOD2. β-Actin was used as an internal control.
- **b** Dual luciferase assay showing the effect on TOP/FOP reporter activity in LSCC cells following the overexpression and silencing of PLOD2.
- **c** Immunoblot assay of c-myc, β-catenin, MDR-1, and MRP protein levels in LSCC cells transfected with PLOD2 and controls. GAPDH was used as an internal control.
By the abnormal activation of signaling pathways, such as the Notch, Hedgehog, NF-κB, Wnt, and PI3K-AKT signaling pathways [13]. CSCs maintain an undifferentiated state. Gene set enrichment analysis (GSEA) was used to predict the activation of a given pathway due to the overexpression of PLOD2. The canonical Wnt signal pathway was found to be significantly related to high PLOD2 expression. It is known that Wnt/β-catenin signaling is activated by oncogenic factors or extracellular cues and drives the CSC phenotype and promotes uncontrolled cell growth and malignant progression [29–31]. Indeed, overactivation of the canonical Wnt pathway has been found in many types of tumors. Notably, head and neck squamous cell carcinoma has been shown to correlate with high Wnt/β-catenin activity to promote epigenetic changes associated with an open chromatin structure and the induction of stem cell gene signatures [32]. Our data show that downstream target genes of Wnt pathway, such as c-myc and β-catenin, were activated in PLOD2-overexpressing LSCC cells. When PLOD2 was overexpressed, the activity of the TOP/FOP reporter was also significantly increased. Hence, PLOD2 may increase the CSC-like properties of cells in laryngeal cancer by activating the Wnt/β-catenin signaling pathway, which is supported by previous reports. Meanwhile, the drug-resistance-related genes MDR-1 and MRP were activated by PLOD2.

CD44 and CD133 are used to identify the CSCs in solid tumors [33]. CD 133 has been suggested to perform several functions, and approximately 16 alternative splicing patterns of CD133 are generated by five alternative promoters in many tissues [34]. Therefore, there is a great need to explore the cross-talk between PLOD2 and CD133. CD44 is a target of the Wnt pathway [35], and overexpression of PLOD2 could promote the expression of downstream genes of Wnt/β-catenin signaling. Hence, we infer that PLOD2 may activate the Wnt pathway, leading to the upregulation of CD44.

Recently, mounting studies have provided evidence that Wnt/β-catenin signaling plays a key role in CSCs by modulating epigenetic changes that define distinct chromatin states [36]. Here, we infer that PLOD2 may promote the translation or activity of Wnt/β-catenin to maintain CSCs in LSCC and thus contribute to cancer cell drug resistance. Further studies are needed to verify our inferences.

**Conclusions**

We provide new insights into the role of PLOD2 in LSCC progression. Our research indicates that PLOD2 is a prognostic indicator in LSCC and confers drug resistance in LSCC by increasing CSC-like properties through activating the canonical Wnt pathway. Further research focus on the underlying mechanism should be performed.

**Abbreviations**

CI: Confidence interval; CSC: Cancer stem cell; CSLC: Cancer stem cell-like; DDP: Cisplatin; HR: Hazard ratio; IHC: Immunohistochemistry; LSCC: Laryngeal squamous cell cancer; MDR: multidrug resistance; PLOD2: Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2; SD: Standard deviation; SI: Staining index

**Acknowledgments**

Not applicable.

**Authors’ contributions**

XS and SZ conceived and designed the study. SZ and GC were responsible for the supervision and coordination of the project. YL, YN, WL, JZ, MX, LC, and XL performed most of the experiments. ZL led the data analysis with inputs from YL and YN. XS and ZL performed statistical analysis of the data. The draft of the manuscript was written by XS and SZ. All authors read and approved the manuscript before submission.

**Funding**

This study was supported by a grant from Guangzhou Science and Technology Project in China [33]. The funder had no role in the design of the study and collection, analysis, and interpretation of data and the writing of the manuscript.

**Availability of data and materials**

The datasets used and/or analyzed in the current study are available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**

The use of human laryngeal cancer tissue was reviewed and approved by the Ethics Committee of Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, and performed in accordance with the approved guidelines. Written informed consent was obtained from the laryngeal cancer patients.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China. 2. Department of Otorhinolaryngology, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, No.106, Zhongshan Er Road, Guangzhou 510080, Guangdong Province, China. 3. Shantou University Medical College, Shantou, Guangdong, China. 4. Head and Neck Surgery of Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China. 5. Department of Otorhinolaryngology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan, Guangdong, China. 6. The Fifth Affiliated Hospital of Guangzhou Medical University, No.621, Gangwan Road, Guangzhou 510700, Guangdong Province, China.

Received: 15 January 2019 Accepted: 8 August 2019

**References**

1. Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67(1):31–50.

2. Zhang D, Tang DG, Rycaj K. Cancer stem cells: regulation programs, immunological properties and immunotherapy. Semin Cancer Biol. 2018; 52(Pt 2):94–106.

3. Ahmed N, Escalona R, Leung D, Chan E, Kannourakis G. Tumour microenvironment and metabolic plasticity in Cancer and Cancer stem cells: perspectives on metabolic and immune regulatory signatures in Chemoresistant ovarian Cancer stem cells. Semin Cancer Biol. 2018;12(53):265–81.

4. Abou-Antoun TJ, Hale JS, Lathia JD, Dombrowski SM. Brain Cancer stem cells in adults and children: cell biology and therapeutic implications. Neurotherapeutics. 2017;14(2):372–84.
5. Vahidani F, Mohammad H, Ali-Hasanzadeh M, et al. MicroRNAs and breast cancer stem cells: potential role in breast cancer therapy. J Cell Physiol. 2019;234(4):3294–306.

6. Li JJ, Shen MM. Prostate stem cells and cancer stem cells. Cold Spring Harb Perspect Med. 2018. https://doi.org/10.1101/cshperspect.a039395.

7. Lenos KJ, Miedema DM, Lodestijn SC, et al. Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer. Nat Cell Biol. 2018;20(10):1193–202.

8. Markowska A, Sajdak S, Hucyzynski A, Rehils S, Markowska J. Ovarian cancer stem cells: a target for oncological therapy. Adv Clin Exp Med. 2018;27(7):1017–20.

9. Pozzi V, Sartini D, Rocchetti R, et al. Identification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell lines. Cell Physiol Biochem. 2015;36(2):784–98.

10. Lee SH, Hyun SK, Kim HB, Kang CD, Kim SH. Potential role of CD133 expression in the susceptibility of human liver Cancer stem-like cells to TRAIL. Oncol Res. 2016;24(8):495–509.

11. Ren F, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol. 2013;19(17):2603–11.

12. Sarvi S, Mackinnon AC, Avlonitis N, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74(5):1554–65.

13. Rabinoivich I, Sebastiao APM, Lima RS, et al. Cancer stem cell markers AlDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma. Eur J Histochim. 2018;62(2943):231–77.

14. Tongtawee T, Wattanawongd W, Simawaranon T, et al. Expression of Cancer stem cell marker CD44 and its polymorphisms in patients with chronic gastritis, precancerous gastric lesion, and gastric Cancer: a cross-sectional multicenter study in Thailand. Biomed Res Int. 2017;2017:438423.

15. Du H, Pang M, Hou X, Yuan S, Sun L. PLOD2 in cancer research. Biomed Pharmacother. 2017;90:670–6.

16. Miyamoto K, Seki N, Matsuhashi R, et al. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br J Cancer. 2016;115(3):354–63.

17. Reis PP, Waldron L, Goswami RS, et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol. 2011;11:46.

18. Noda T, Yamanoto H, Takekawa I, et al. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int. 2012;32(1):110–8.

19. Gillies DM, Bajpai S, Wong CC, et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res. 2013;11(5):466–66.

20. Eisinger-Mathason TS, Zhang M, Oiu Q, et al. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 2013;3(10):1190–205.

21. Kurozumi A, Kato M, Goto Y, et al. Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cancer stem cells. Mol Cancer. 2013;12(10):1190.

22. Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem Cells. 2006;24(13–12)

23. Shimoda M, Ota M, Okada Y. Isolation of Cancer stem cells by side population method. Methods Mol Biol. 2018;1692:49–59.

24. Verano-Braga T, GorskiV, Munthe S, Sorensen MD, Kristensen BW, Kjeldsen F. SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. Oncotarget. 2018;9(10):9400–14.

25. Rajkumar T, Sabha K, Wijalakshmi N, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011;11:80.

26. Blanco MA, LeRoy G, Khan Z, et al. Global secretome analysis identifies novel mediators of bone metastasis. Cell Res. 2012;22(9):1335–55.

27. Xu Y, Zhang L, Wei Y, et al. Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion. Oncotarget. 2017;8(38):62401–13.

28. Chen Y, Guo H, Terajima M, et al. Lysyl hydroxylase 2 is secreted by tumor cells and can modify collagen in the extracellular space. J Biol Chem. 2016;291(50):25799–808.

29. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):19–26.

30. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346(6205):1248012.

31. Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(5):985–99.

32. West P, Fang L, Zhu Q, et al. Wnt/beta-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. EMBO J. 2013;32(14):1977–89.

33. da Silva-Diz V, Lorenzo-Sanz L, Bernat-Peguera A, Lopez-Cerda M, Munoz P. Cancer cell plasticity: impact on tumor progression and therapy response. Semin Cancer Biol. 2018;53:48–58.

34. Jang JW, Song Y, Kim SH, Kim J, Seo HR. Potential mechanisms of CD133 in cancer stem cells. Life Sci. 2017;184:25–9.

35. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–67.

36. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 2009;10(4):276–86.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.